Quarterly Updates10 Nov 2025, 06:22 pm
SMS Pharmaceuticals Reports 80% YoY PAT Growth in Q2FY26, Driven by Backward Integration and Operating Leverage
AI Summary
SMS Pharmaceuticals Limited (SMS Pharma) has announced its unaudited financial results for the quarter ended September 30, 2025. The company reported an 80% YoY growth in PAT, driven by higher volumes, market share gains, and backward integration. The company's revenue grew 23% YoY, gross margin expanded 30% YoY, and EBITDA increased 54% YoY. The company is on track to achieve its FY26 outlook with a focus on product mix optimization, backward integration, economies of scale, and a new product pipeline.
Key Highlights
- Revenue grew 23% YoY, driven by higher volumes and market share gains
- Gross margin expanded 30% YoY, driven by backward integration
- EBITDA increased 54% YoY, aided by operating leverage
- PAT stood at X25.32 crore, up by 80% YoY; Record highest in a quarter
- X280 crore Capex programme on track for completion by November 2026